Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piracetam SCHEMBL20172 | 0.83 | TSHR (1.00) | TSHRSMN1; SMN2HTTALDH1A1CA12 | |
| Piracetam SCHEMBL6140872 | 0.83 | TSHR (1.00) | TSHRSMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL24263535 | 0.78 | TSHR (0.89) | TSHRSMN1; SMN2HTTALDH1A1LMNA | |
| Piracetam SCHEMBL28029064 | 0.77 | TSHR (0.86) | TSHRSMN1; SMN2HTTALDH1A1CA12 | |
| SCHEMBL1532937 | 0.76 | TSHR (0.85) | TSHRSMN1; SMN2HTTALDH1A1KMT2A | |
| 4,4'-Methylenedianiline SCHEMBL20770172 | 0.74 | TSHR (0.69) | TSHRSMN1; SMN2HTTALDH1A1POLB | |
| SCHEMBL2774412 | 0.74 | L3MBTL1 (0.66) | SMN1; SMN2HTTALDH1A1CA12CA1 | |
| SCHEMBL1254047 | 0.73 | L3MBTL1 (0.69) | SMN1; SMN2HTTALDH1A1POLBKMT2A | |
| SCHEMBL8552055 | 0.72 | — | — | |
| SCHEMBL14199640 | 0.72 | ALDH1A1 (0.51) | TSHRSMN1; SMN2HTTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765379-A4 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELATED METHODS OF USE | TRANSFORM PHARMACEUTICALS INC (US) | 2009-05-27 | — | — | EP | claimed |
| EP-1765379-A2 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELATED METHODS OF USE | Transform Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006007448-A2 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELATED METHODS OF USE | TRANSFORM PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | WO | claimed |
| US-9173391-B2 | Crystalline complexes of 4-hydroxy benzoic acid and selected pesticides | BASF SE (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2496077-B1 | CRYSTALLINE COMPLEXES OF 4-HYDROXY BENZOIC ACID AND SELECTED PESTICIDES | BASF SE (DE) | 2014-08-20 | — | — | EP | disclosed |
| EP-2496077-A2 | CRYSTALLINE COMPLEXES OF 4-HYDROXY BENZOIC ACID AND SELECTED PESTICIDES | BASF SE (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120220463-A1 | Crystalline Complexes of 4-Hydroxy Benzoic Acid and Selected Pesticides | BASF SE (DE) | 2012-08-30 | — | — | US | disclosed |
| WO-2011054741-A2 | CRYSTALLINE COMPLEXES OF 4-HYDROXY BENZOIC ACID AND SELECTED PESTICIDES | BASF SE (DE) | 2011-05-12 | — | — | WO | disclosed |
| US-7803786-B2 | Pharmaceutical co-crystal compositions and related methods of use | TRANSFORM PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1765379-A4 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELATED METHODS OF USE | TRANSFORM PHARMACEUTICALS INC (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20070299033-A1 | stavudine:melamine co-crystal or stavudine:2-aminopyridine co-crystal; therapeutics; shelf-life, bioavailability | TRANS FORM PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1765379-A2 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELATED METHODS OF USE | Transform Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006007448-A2 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELATED METHODS OF USE | TRANSFORM PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299033-A1 | stavudine:melamine co-crystal or stavudine:2-aminopyridine co-crystal; therapeutics; shelf-life, bioavailability | MTAP, TYMP, TPMT | TSHR 1749/4885SMN1; SMN2 189/4885HTT 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.